- Previous Close
1.5500 - Open
0.0000 - Bid 1.4000 x --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 2.6850 - Volume
32,348 - Avg. Volume
1,177,421 - Market Cap (intraday)
6.54M - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, develops an immunoassay test for the CIZ1B cancer biomarker for the early detection of lung cancer in the United Kingdom. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
www.cizzlebiotechnology.comRecent News: CIZ.L
View MorePerformance Overview: CIZ.L
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CIZ.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CIZ.L
View MoreValuation Measures
Market Cap
6.14M
Enterprise Value
5.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.74
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.72%
Return on Equity (ttm)
-157.81%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.7M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
816k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-156.12k